NCI-2022-04033

A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

This is a Phase I study where they'll test a new treatment called CS5001 on people with advanced solid tumors and lymphomas. They'll gradually increase the amount of CS5001 to find the safest dose and see how it affects the tumors. The goal is to check if CS5001 is safe, how it moves through the body, and if it can help fight these types of cancers.

Phase I study: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05279300

Clinical Trial Site: Columbia

To see all available clinical trials click here.